Nab-Paclitaxel/carboplatin in elderly patients with advanced squamous non-small cell lung cancer: a retrospective analysis of a Phase III trial.

ABSTRACT:

Background

Limited data on elderly patients with squamous advanced non-small cell lung cancer (NSCLC) preclude optimal treatment. Here, we report the outcomes of a retrospective analysis of a subset of patients ≥70 years with squamous histology from the Phase III trial that evaluated nab-paclitaxel/carboplatin vs paclitaxel/carboplatin.

Patients and methods

Patients with stage IIIB/IV NSCLC received (1:1) nab-paclitaxel 100 mg/m² on days 1, 8, and 15 or paclitaxel 200 mg/m² on day 1, both with carboplatin area under the curve 6 mg×min/mL on day 1 every 3 weeks. The primary endpoint was independently assessed overall response rate as per the Response Evaluation Criteria in Solid Tumors v1.0. Secondary endpoints included progression-free survival, overall

SUBMITTER: Gridelli C 

PROVIDER: S-EPMC5973475 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature